In an historic achievement, Dr. Feras Khaliel and his team at King Faisal Specialist Hospital & Research Centre (KFSHRC) in Riyadh, Saudi Arabia, successfully performed the world’s first fully robotic heart transplant on a 16-year-old patient with end-stage heart failure. This innovative procedure reduced recovery times and surgical risks, setting a new standard for cardiac […]
A study from Karolinska Institutet reveals that low levels of anti-phosphorylcholine antibodies may indicate increased risk of heart disease in older women, potentially paving the way for improved risk assessment and preventive strategies.
The American Heart Association and American College of Cardiology have jointly published an updated guideline for managing cardiovascular risks in patients undergoing noncardiac surgery, reflecting a decade of new evidence since the last update in 2014.
New research reveals that patients with stable coronary artery disease who quit smoking at any point after diagnosis can reduce their risk of major cardiovascular events by nearly 50%. The study, presented at ESC Congress 2024, also found that merely reducing smoking habits had minimal impact on cardiovascular risk.
A series of groundbreaking studies from Poland have shed new light on the prevalence and impact of lipoprotein(a) [Lp(a)] on cardiovascular health, prompting calls for routine measurement of this important biomarker.
A groundbreaking titanium artificial heart with a single moving part has been successfully implanted in a patient with end-stage heart failure, potentially revolutionising treatment options for those awaiting transplantation.
Royal Philips has announced the successful first implantation of its Duo Venous Stent System following premarket approval from the U.S. Food and Drug Administration. The device is indicated for treating symptomatic venous outflow obstruction in patients with chronic venous insufficiency (CVI).
Royal Philips, a leader in health technology, has launched a new cardiac care platform aimed at transforming diagnostic cardiology in Europe, the Middle East, and Africa. The Philips Cardiac Workstation utilises sophisticated algorithms to expedite the collection and processing of electrocardiograph (ECG) data, potentially streamlining care and helping to prioritise high-risk patients.
A groundbreaking study involving over 17,000 patients has demonstrated the safety of pulsed field ablation (PFA) for treating atrial fibrillation. The MANIFEST-17K trial, led by researchers from the Icahn School of Medicine at Mount Sinai, provides compelling evidence that this novel technique avoids many of the complications associated with traditional thermal ablation methods.
A comprehensive study published in The BMJ [1] reveals a complex picture of cardiovascular disease (CVD) trends in the UK over the past two decades. While rates of coronary heart disease have declined significantly, this progress has been offset by rising incidences of other cardiovascular conditions.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com
PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.
BiVACOR